Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Eli Lilly (LLY.US) makes another move! Acquires Calytrix for up to $1.5 billion, betting on rare blood cancer therapies

Eli Lilly (LLY.US) makes another move! Acquires Calytrix for up to $1.5 billion, betting on rare blood cancer therapies

智通财经智通财经2026/11/16 13:22
Show original

Eli Lilly has agreed to acquire the privately held Calytrix Bio Inc. in a deal valued at up to $1.5 billion.

According to Jinse Finance APP, Eli Lilly (LLY.US) has agreed to acquire privately held Calytrix Bio Inc. in a deal valued at up to $1.5 billion. This is the latest move by Eli Lilly in its ongoing acquisitions and expansion into the oncology and autoimmune disease fields.

Eli Lilly stated in a press release on Monday that the transaction includes an undisclosed upfront cash payment, along with milestone payments contingent on achieving specific clinical targets.

Following the announcement, Eli Lilly's U.S. stock rose about 0.6% in pre-market trading.

It is understood that Eli Lilly is widely known for its blockbuster weight-loss drug Zepbound, and as a leading global pharmaceutical company, it continues to make large-scale acquisitions, exploring new areas and strengthening its technological capabilities in key fields, aiming to establish new growth drivers beyond its diabetes and obesity businesses.

Calytrix is a company still in the research and development stage, focusing on antibody therapies for rare hematological tumors. This acquisition follows Eli Lilly's earlier acquisition of Ajax Therapeutics in the same field earlier this year.

Calytrix Bio was founded in 2025 by JPMorgan’s life sciences private equity team, with initial funding from JPMorgan's venture capital division and Westlake BioPartners, while Avoro Ventures later also participated. The company was established with the aim of tackling a group of rare blood cancers originating in the bone marrow.

The biotech company's core pipeline is an engineered targeted protein designed to address gene mutations driving two chronic hematologic diseases: primary thrombocythemia and myelofibrosis. Current therapies for these two conditions can only manage symptoms and complications.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!